يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"Conductes biliars - Càncer - Tractament"', وقت الاستعلام: 0.63s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Yamamoto N Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. Tolcher A NEXT Oncology, San Antonio, TX, USA. Hafez N Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA. Lugowska I Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland. Ramlau R Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland. Macarulla T Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Avaluació de resultats (Assistència sanitària), Conductes biliars - Càncer - Tractament, Quimioteràpia combinada, Proteïnes supressores de tumors, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms::Bile Duct Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Poly-ADP-Ribose Binding Proteins::Tumor Suppressor Protein p53, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar::neoplasias de los conductos biliares, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas transportadoras::proteínas de unión a poli-ADP-ribosa::proteína supresora de tumor p53

    وصف الملف: application/pdf

    العلاقة: OncoTargets and Therapy;17; https://doi.org/10.2147/OTT.S440979Test; Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, et al. Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. Onco Targets Ther. 2024 Mar 29;17:267–80.; https://hdl.handle.net/11351/11357Test; 001194678500001

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Serra-Camprubí Q, Lupión-Garcia N, Llop-Guevara A, Molina C, Querol J, Yáñez-Bartolomé M, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Miquel JM, Nuciforo PG, Serra V, Peiró S, Tian TV Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Verdaguer H, Castet F, Fabregat-Franco C, Tabernero J, Macarulla T Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Oliveros W Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain. Vila-Casadesús M, Vivancos A Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Frigola J Clinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Arribas J Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain. Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical Cancer Research;29(2); https://doi.org/10.1158/1078-0432.CCR-22-2551Test; info:eu-repo/grantAgreement/ES/PE2017-2020/RYC2020-029098-I; info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-108008RJ-I00; info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00898; info:eu-repo/grantAgreement/ES/PE2013-2016/RYC-2017-22249; Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, et al. Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation. Clin Cancer Res. 2023 Jan 17;29(2):432–45.; https://hdl.handle.net/11351/9416Test; 000922278000001

  3. 3
    دورية أكاديمية

    المؤلفون: DOPAZO, CRISTINA, Charco, Ramon

    المساهمون: Institut Català de la Salut, Dopazo C, Charco R Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Hepatoma Research;9; http://dx.doi.org/10.20517/2394-5079.2022.75Test; Dopazo C, Charco R. Liver Transplantation for perihilar cholangiocarcinoma. Do we need to move forward? Hepatoma Res. 2023 Mar 29;9:10.; https://hdl.handle.net/11351/10179Test

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Zimmer K, Kocher F, Amann A Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University Innsbruck (MUI), Innsbruck, Austria. Untergasser G, Kircher B Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University Innsbruck (MUI), Innsbruck, Austria. Tyrolean Cancer Research Institute, Innsbruck, Austria. Baca Y Caris Life Sciences, Phoenix, AZ, USA. Macarulla T, Tabernero J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: NPJ Precision Oncology;7; https://doi.org/10.1038/s41698-023-00409-5Test; Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, et al. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ Precis Oncol. 2023 jul 3;7:64.; https://hdl.handle.net/11351/9989Test

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Bekaii-Saab TS Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. Valle JW Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, The University of Manchester, Manchester, UK. Van Cutsem E Department of Oncology, University of Leuven, Leuven, Belgium. Rimassa L Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Furuse J Department of Medical Oncology, Kyorin University, Tokyo, Japan. Ioka T Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan. Macarulla T Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Future Oncology;16(30); https://doi.org/10.2217/fon-2020-0429Test; Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. 2020 Oct;16(30):2385–99.; https://hdl.handle.net/11351/6560Test; 000595834200002

  6. 6

    المساهمون: Institut Català de la Salut, [Serra-Camprubí Q, Lupión-Garcia N, Llop-Guevara A, Molina C, Querol J, Yáñez-Bartolomé M, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Miquel JM, Nuciforo PG, Serra V, Peiró S, Tian TV] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Verdaguer H, Castet F, Fabregat-Franco C, Tabernero J, Macarulla T] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Oliveros W] Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain. [Vila-Casadesús M, Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Frigola J] Clinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arribas J] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer, Monforte de Lemos, Madrid, Spain. Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Barcelona Supercomputing Center

    المصدر: Scientia

    وصف الملف: application/pdf